Management of rare mutations in non-small cell lung cancer (NSCLC) – PART 1: MET, ROS1, and ALK
Why do we make a fuss about rare mutations in NSCLC? In 2015, they only made up about 1-2%...
NSCLC patients
Why do we make a fuss about rare mutations in NSCLC? In 2015, they only made up about 1-2%...